
About Madrigal
Madrigal is a publicly listed company based in Lexington (United States) founded in 2000. Small molecule drugs are developed for cancer and inflammatory diseases. It operates on a HealthTech model. Madrigal has raised $90 million across 3 funding rounds from investors including Caxton Associates, Galleon Group and Military Health. The company has 37 employees. Madrigal has completed 1 acquisition, including Madrigal Pharmaceuticals. Madrigal offers products and services including MASH Treatment. Its focus areas include Biotechnology and Liver Disease Therapeutics. Its legal entity is Madrigal Pharmaceuticals, Inc. Its competitors include Adicet Bio, Orca Bio and Ossium Health; 3 of its 3 listed competitors have raised funding.
Company details
Madrigal Pharmaceuticals, Inc. is engaged in developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a severe liver condition. The companys efforts are directed towards halting or reversing liver scarring and resolving MASH to prevent complications like cirrhosis. Operating within the biopharmaceutical sector, Madrigal has achieved a significant milestone with the first FDA-approved treatment for MASH. Their solutions target high unmet medical needs in liver disease management across the United States and Europe.
- Headquarters Lexington, United States
- Employees 37
- Stage Public
- SectorsHealthcare
- Phoneβ’β’β’β’ β’β’β’β’
- Website syntapharma.com
- Social LinkedIn X Facebook
- Legal Name Madrigal Pharmaceuticals, Inc.
- Annual Revenue$180.13 M (USD)as on Dec 31, 2024
- Net Profit-$465.89 M (USD)-25as on Dec 31, 2024
- EBITDA-$497.88 M (USD)-31as on Dec 31, 2024
- Total Equity Funding$90M (USD)
in 3 rounds
- Latest Funding Round$999.7K (USD), Grant
Apr 2011
- InvestorsCaxton Associates
& 2 more
- Employee Count37
- Investments & Acquisitions
Products & Services of Madrigal
Madrigal offers a comprehensive portfolio of products and services, including MASH Treatment.
A treatment for metabolic dysfunction-associated steatohepatitis is provided.
Funding Insights of Madrigal
Madrigal has successfully raised a total of $90M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $999.7 thousand completed in April 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $90M
- Total Rounds 3
- Last Round Grant β $999,699
- First Round $50M
(Jan 2004)
- Investors Count 3
All 3 funding rounds of Madrigal with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2011 | $999,699 | Grant | β | β | |
| Oct 2006 | $40M | Private Equity Round | β | β | β |
| Jan 2004 | $50M | Series C | β | β |
3 investors in total: 3 institutional.
Investors in Madrigal
Madrigal has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Caxton Associates, Galleon Group and Military Health.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Diversified asset management is provided by Caxton Associates. | 1983 | caxton.com | New York, United States | |
| galleongrp.com | ||||
Administers health care and support for military personnel and operations. | health.mil | Falls Church, United States |
Investor details for Madrigal
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Madrigal
288 people are tracked at Madrigal (142 in leadership, 6 in board & advisors, 140 in team); the tracked headcount is 37.
| Name | Role | Group |
|---|---|---|
Hetal Panchal | Sr. Director, Data Platform And Analytics | Leadership |
Jason Gay | Regional Business Director | Leadership |
Ron Marchessault | Vice President, Head Of Market Access | Leadership |
Kristine Grigoryan | Payroll Director | Leadership |
Zara Gaudioso | Director Human Resources Operations | Leadership |
Parth Patel | Executive Director, AI And Data Science | Leadership |
Nancy B. | Director, Commercial Training & Development | Leadership |
Christopher Milazzo | Sr. Director, Clinical Practice Liaisons | Leadership |
Vanessa MacGregor | Director, Specialty Pharmacy: Market Access | Leadership |
Amir Karimzadeh | Senior Director -nash Medical Sciences | Leadership |
Scott Farris | Sr Director, Health Systems National Accounts | Leadership |
Ken Liu | Senior Director, National Accounts, US Market Access | Leadership |
Brad Giglio | Senior Director National Accounts | Leadership |
Amber Pace | Northeast Regional Sales Director | Leadership |
John O'Donnell | Vice President, Global Health Economics And Outcomes Research | Leadership |
Carlos Blocker | Regional Sales Director | Leadership |
Lauren van Den Heuvel | Senior Director, Market Access Strategy & Operations | Leadership |
Alexandre Felizardo | Executive Director- Market Access | Leadership |
Bob O'Rourke | Vice President, Talent Access | Leadership |
Kelley Anne Bruni | Director, Key Accounts, Health Systems | Leadership |
268 more people are available in the full profile.
Complete people profiles for Madrigal
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Madrigal
Madrigal has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Madrigal Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis | madrigalpharma.com | Conshohocken, United States | 2011 | Apr 2016 | β’β’β’β’ |
Complete acquisition details for Madrigal
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Madrigal
5 dated milestones of Madrigal across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Madrigal is founded.
- Funding First funding round of $50.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $1,000K.
- Acquisition Acquires Madrigal Pharmaceuticals.
Competitors of Madrigal
Madrigal has 3 listed competitors in our database, 3 of them funded. They include Adicet Bio, Orca Bio and Ossium Health.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| adicetbio.com | 2014 | Menlo Park, United States | $51M | 86 | Immune cell therapies for cancer treatment are developed. | |
| orcabio.com | 2016 | Menlo Park, United States | $300M | 66 | Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | |
| ossiumhealth.com | 2016 | San Francisco, United States | $125.41M | Ossium Health is focused on bioengineering for improved health. |
Detailed competitors of Madrigal
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Madrigal (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Madrigal
Complete news archive for Madrigal
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Madrigal
Madrigal was founded in 2000 and raised its 1st funding round 4 years after it was founded.
Madrigal is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Madrigal is a funded company, having raised a total of $90M across 3 funding rounds to date. The company's 1st funding round was a Series C of $50M, raised on Jan 2004.
Madrigal has 37 employees.
Annual revenue of Madrigal is $180.13M as on Dec 31, 2024.
Madrigal Pharmaceuticals, Inc. is engaged in developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a severe liver condition. The companys efforts are directed towards halting or reversing liver scarring and resolving MASH to prevent complications like cirrhosis. Operating within the biopharmaceutical sector, Madrigal has achieved a significant milestone with the first FDA-approved treatment for MASH. Their solutions target high unmet medical needs in liver disease management across the United States and Europe.
Madrigal's top competitors include Orca Bio, Ossium Health and Adicet Bio.
Madrigal offers MASH Treatment.
Madrigal has made 1 acquisition, including Madrigal Pharmaceuticals.
Madrigal has 3 investors. Key investors include Caxton Associates, Galleon Group, and Military Health.
Madrigal operates through Madrigal Pharmaceuticals, Inc..
